Measuring the impact of monoclonal antibody drugs in cancer and rheumatoid arthritis

自第一批MAB药物获得批准以来，已经过去了40多年。今天，世界上最畅销的药物中，有六种是MAB疗法。MAB药物目前占所有引入的新疗法的三分之一。尽管他们取得了成功，但还没有进行系统的研究，以评估有多少患者服用了这种药物，以及他们在多大程度上造福了他们的生命。该项目的目标是确定最畅销的单抗药物对癌症和类风湿性关节炎的影响，这两个关键疾病领域的这种治疗已经产生了一些最深刻的影响。在这项研究中，我们将根据临床效益(延长寿命和质量改善)来衡量效益。以前的研究估计了给定试验中有限数量的患者的益处。在这个项目中，我们建议将估计收益乘以特定时间段内的用户数量。

It is now over 40 years since the first mab drugs were approved. Today six out of ten of the best selling drugs in the world are mab therapeutics. Mab drugs currently make up a third of all introduced new treatments. Despite their success, no systematic study has been done to assess how many millions of patients have taken such drugs and the extent to which they have benefited their lives. The goal of this project is to determine the impact of the best-selling mAb drugs for cancer and rheumatoid arthritis, two key disease areas where such therapy has had some of its most profound impact. In this study we will measure benefit in terms of clinical benefit (life extension and quality improvement). Previous studies have estimated benefit for a limited number of patients in a given trial. In this project we propose to multiply the estimated benefits by the number of users over a specified period.